On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb

  • BiondVax is a biotechnology company3` focused on developing, manufacturing, and commercializing innovative immunotherapeutic products
  • The company is developing nanosized antibodies (“NanoAbs”) addressing large market diseases underserved by current treatments, with its lead candidate targeting COVID-19
  • The FDA recently revoked the sole authorization of a COVID prophylactic, Evusheld, citing the inability of the monoclonal antibody cocktail to neutralize emerging subvariants of the Omicron variant
  • BiondVax’s lead NanoAb candidate shows superior advantages to monoclonal antibodies, with the data gathered strengthening the value proposition of the COVID-19 NanoAb as a safe, efficacious, and convenient therapeutic and prophylactic drug

The Food and Drug Administration (“FDA”) recently withdrew the authorization of AstraZeneca PLC (NASDAQ: AZN)’s Evusheld, a combination of two monoclonal antibodies (“mAbs”), which was being marketed as a pre-exposure prophylaxis to prevent COVID-19 infection among people with moderate to severe immune compromise (https://ibn.fm/zmmHn). The agency revoked the authorization citing the expectation that Evusheld may not neutralize the XBB.1.5 sub-variant of the Omicron variant. In fact, according to the FDA, sublineages not neutralized by the antibody therapy are presently causing at least 90% of infections.

Evusheld’s cancellation is the latest in a series of withdrawals, with the FDA having previously revoked the authorization for emergency use of bebtelovimab, another monoclonal antibody therapy, because it was not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1 (https://ibn.fm/IhUqw).

“Beyond Evusheld, the virus’s evolution has also left the country without any antibody therapies for patients once they are infected,” reads an article in Stat News (https://ibn.fm/Vm5sL). However, BiondVax Pharmaceuticals (NASDAQ: BVXV), a Jerusalem-based biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, is working on changing this grim reality. In fact, the company’s leading inhaled nanosized antibody (“NanoAb”) candidate, which is currently being prepared for clinical trials, has shown neutralization of all relevant Omicron subvariants.

“Indeed, the emergence of new variants remains a concern, and NanoAb therapeutics have the potential to quickly and effectively address new variants,” wrote CEO Amir Reichman in his 2022 letter to shareholders (https://ibn.fm/uOpcQ). “Our collaborators at the Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”) have generated libraries each with ~300 million COVID-19 NanoAb candidates, as compared to mAb libraries that contain only thousands of options. Thus, as new variants emerge, we would expect to be in a position to rapidly develop a new neutralizing NanoAb.”

With the cancellation of these monoclonal antibody therapies, originally authorized to help protect high-risk populations from the ever-evolving SARS-COV-2 virus, the value of BiondVax’s NanoAb-based COVID-19 therapeutic currently under development has never been clearer.

Developed in collaboration with Germany-based MPI and UMG, the alpaca-derived NanoAbs have demonstrated unique characteristics such as greater formulation advantages, stability at high temperatures, and binding affinity than mAbs. Moreover, NanoAbs have shown strong potential for superior clinical outcomes, safety, and patient convenience at lower costs than mAbs, which have generated billions in annual commercial sales.

In fact, BiondVax’s ongoing preclinical in vivo study is convincingly demonstrating the unique capabilities of its inhaled COVID-19 therapy. As reported by the company in November 2022, animal models treated with BiondVax’s inhaled NanoAbs experienced a milder and shorter illness (https://ibn.fm/FTm6x). The company also announced early January 2023 that the inhaled therapy virtually eliminated the SARS-CoV-2 virus from the animal models’ lungs (https://ibn.fm/2GKAy). In the most recent announcement, BiondVax reported its inhaled therapeutic virtually prevented illness when administered prophylactically. Obviously, this data strengthens the value proposition of the COVID-19 NanoAb as both a therapeutic and prophylactic drug.

“COVID vaccine uptake is declining, effectiveness wanes over a short period of time, and vaccination campaigns demand vast health care system resources. We believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID-19 illness,” commented Reichman in a January 23 news release reporting the prophylactic properties of the NanoAbs (https://ibn.fm/YpEYG).

BiondVax aims to fill the existing void in COVID prophylactics and treatments, which, as sales figures indicate, is strong. AstraZeneca, for instance, reported that Evusheld had generated $1.451 billion in revenue from Q1 through Q3 2022 (https://ibn.fm/UPZ8M); and even with its limitations, Paxlovid, an antiviral medication developed by Pfizer Inc. (NYSE: PFE), generated $18.9 billion in sales in 2022 (https://ibn.fm/6sOdX).

BiondVax’s NanoAbs may be the key to an effective, economical, and easy to use solution for COVID therapeutics and prophylactics. With human clinical trials scheduled for later this year it certainly makes sense to keep BVXV on the radar.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered